



2203-01: Synexis Dry Hydrogen Peroxide Biodefence System

Evaluated by the Rapid Review panel (RRP)

22 March 2019

Evaluation Level E5: Evidence presented does not demonstrate that the product is more efficient or efficacious at improving infection prevention and control interventions to reduce healthcare associated infections than other available products currently in use.

- Dry Hydrogen Peroxide (DHP) technology is claimed to offer a novel adjunct to normal disinfection, ie a continuous automated (low-level, slow disinfection) process that can be used to supplement any of the more traditional methodologies.
- From the evidence supplied, environmental microbial burdens appear lowered by exposure to DHP, but it is unclear if the initial levels examined represented significant contamination levels. A direct association with a reduction in healthcare associated infections has not been evidenced.

Evaluation disclaimer: The RRP does not formally review cost-effectiveness or implementation barriers during its evaluation of products; these factors may be considered in a separate process. It is the responsibility of the applicant to carry out any further required development, including trials, cost-effectiveness assessments or product implementation within the NHS. All statements comparing the efficiency or efficacy of products are in the context of products available for use to the NHS at the date of evaluation.